PARP inhibitors for prostate cancer
Source : https://pubmed.ncbi.nlm.nih.gov/37783649/
Poly(ADP-ribose) polymerase (PARP) inhibitors have transformed the treatment landscape for patients with metastatic castration-resistant prostate cancer (mCRPC) and alterations in DNA damage response genes. This has also led to widespread...
PARP inhibitors have revolutionized mCRPC treatment, necessitating genomic testing for effective therapy. Ongoing research is crucial for understanding biomarkers, resistance mechanisms, and optimizing combination therapies for enhanced patient outcomes.
Prostate Cancer Theranostics With 177Lu-PSMA
Source : https://pubmed.ncbi.nlm.nih.gov/38570288/
This review paper highlights the transformative role of PSMA-targeted diagnostics and therapy in prostate cancer management, particularly focusing on 177 Lu-PSMA-617, approved by the FDA and EMA for metastatic castration-resistant...
PSMA-targeted therapy with 177Lu-PSMA represents a significant advance in prostate cancer management, advocating for its integration into multimodal approaches and necessitating further studies to optimize treatment outcomes and long-term prognosis.
Vaccines as treatments for prostate cancer
Source : https://pubmed.ncbi.nlm.nih.gov/36879114/
Prostate cancer is a leading cause of death in men worldwide. For over 30 years, growing interest has focused on the development of vaccines as treatments for prostate cancer, with...
This evidence suggests that, in the future, prostate cancer vaccines might be used to activate and expand tumour-specific T cells as part of combination approaches with agents that target tumour-associated immune mechanisms of resistance.
Targeting Glutamine Metabolism in Prostate Cancer
Source : https://pubmed.ncbi.nlm.nih.gov/36959101/
Glutamine is a conditionally essential amino acid important for cancer cell proliferation through intermediary metabolism leading to de novo synthesis of purine and pyrimidine nucleotides, hexosamine biosytnehsis, fatty acid synthesis...
The druggability of prostate cancer glutamine metabolism is more readily achievable with our greater understanding of tumor metabolism and the advent of selective glutaminase inhibitors that have proven safe and tolerable in early-phase clinical trials.
Resistance to prostate cancer treatments
Source : https://pubmed.ncbi.nlm.nih.gov/35978491/
A review of the current treatment options for prostate cancer and the formation of resistance to these regimens has been compiled including primary, acquired, and cross-resistance. The diversification of the...
Addressing prostate cancer's treatment challenges requires personalized approaches due to tumor heterogeneity and treatment resistance, emphasizing ongoing research into novel therapies and clinical trials for improved outcomes.